Axsome Therapeutics, Inc.
News
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of "Buy" from Analysts
Ticker Report Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have received a consensus rating of "Buy" from the fourteen brokerages that are presently covering the company, MarketBeat.com...\n more…
Bank of New York Mellon Corp Raises Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Ticker Report Bank of New York Mellon Corp increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 7.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 165,564 shares...\n more…
Axsome Therapeutics (NASDAQ:AXSM) Earns Overweight Rating from Cantor Fitzgerald
Ticker Report Axsome Therapeutics (NASDAQ:AXSM - Get Free Report)s stock had its "overweight" rating reaffirmed by stock analysts at Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They...\n more…
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Zacks Investment Research It has been about a month since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have added about 4.5% in that time frame, outperforming the S&P 500.Will the recent positive...\n more…
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Simply Wall St You may think that with a price-to-sales (or "P/S") ratio of 15.4x Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) is a stock...\n more…
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from Needham & Company LLC
Ticker Report Needham Company LLC reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM - Free Report) in a research note released on Thursday morning, Benzinga reports. Needham &...\n more…